Skip to content
DNDi Logo
  • DNDi INTERNATIONAL
  • DNDi JAPAN
  • DNDi LATIN AMERICA
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Menu
  • ABOUT DNDi
    • ABOUT DNDi NORTH AMERICA
    • OUR TEAM
    • BOARD OF DIRECTORS
    • OUR PUBLICATIONS
    • FINANCIALS
    • JOBS
    • Close
  • DISEASES & PROJECTS
  • ADVOCACY
  • MEDIA CENTER
  • DONATE
  • CONTACT
    • Close
  • Home

Media Center

RSS SCIENTIFIC ARTICLES

  • Barriers to access to visceral leishmaniasis diagnosis and care among seasonal mobile workers in Western Tigray, Northern Ethiopia: A qualitative study
  • Validation of Apolipoprotein A1 and Fibronectin fragments as markers of parasitological cure for congenital Chagas disease in children treated with benznidazole
  • Response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries

RSS PRESS RELEASES

  • European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness
  • New hope for PKDL patients in Africa as clinical trial aims to make treatment safer and easier
  • DNDi and Fiocruz launch project to expand access to diagnosis and treatment for Chagas disease in Brazil

RSS NEWS

  • Making Medical History
  • 11th DNDi Partners’ Meeting celebrates African leadership in innovation for R&D and access to medicines
  • Joelle Tanguy appointed Director of External Affairs at DNDi

RSS IN THE MEDIA

  • Le Parisien: “La «maladie du sommeil» amenée à disparaître”
  • The Huffington Post: “How war could undermine one of medicine’s brightest success stories”
  • Science Africa: “Fexinidazole could help end sleeping sickness in Africa by 2020”

RSS EVENTS

  • 14th International Conference on Vectors and Vector Borne Diseases
  • International Conference on Innovations for the Elimination and Control of Visceral Leishmaniasis (IEC-VL)
  • 5th Symposium on Drug Design and Development for Neglected Diseases

RSS Scientific Articles

  • Barriers to access to visceral leishmaniasis diagnosis and care among seasonal mobile workers in Western Tigray, Northern Ethiopia: A qualitative study
  • Validation of Apolipoprotein A1 and Fibronectin fragments as markers of parasitological cure for congenital Chagas disease in children treated with benznidazole
  • Response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries
  • Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India

About DNDi

Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected patients.

Subscribe

Sign up for the E-news newsletter! By subscribing, you agree that all info submitted will be processed according to our Privacy Policy. You can unsubscribe any time.

I want to receive

Connect

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
  • Events

DNDi Worldwide

  • DNDi regional offices
  • DNDi Japan のサイトへはこちらから.
  • DNDi Latin America website
  • DNDi North America website
  • GARDP

Donate

Support research for neglected disease treatments by making a gift

Authorize.net Seal

Charity Status

GuideStar Gold Participantnewyork-ac-seal-vertical-black-web

Social Mission Ratio

Social Mission Ration 2017

  • PRIVACY POLICY
  • TERMS OF USE
  • ACCEPTABLE USE POLICY
  • COOKIE POLICY
  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License
We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser. Read Cookie Policy. Close